Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress -ATH434 Phase 2 Data to be Presented at Opening Plenary Session - MELBOURNE, AUSTRALIA AND SAN FRANC

Alterity Therapeutics Announces Multiple Oral

and Poster Presentations to be Featured at the International MSA Congress

2 Data to be Presented at Opening Plenary Session -

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA

- 7 May 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology

company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster

presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International

MSA Congress taking place May 9 - 11, 2025 in Boston, MA, USA. The Congress is presented by Mission MSA, a non-profit organization dedicated

to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research

funding, and community engagement.

David Stamler, M.D., Chief Executive Officer of

Alterity, commented, "We are excited to play a prominent role at the MSA Congress which brings together a noteworthy group of physicians

and scientists as well as patients and care partners, all of whom are focused on advancing MSA research and care. Mission MSA is one of

the primary patient education and advocacy organizations for the disease in the U.S., and we are also proud to support the event as a

sponsor. We look forward to presenting our double-blind Phase 2 data for ATH434 as well as our bioMUSE natural history study with our

colleagues at Vanderbilt University Medical Center. Our clinical advancements in MSA continue to generate significant interest throughout

the community, bolstered by the recent Fast Track Designation for ATH434 that was granted by the US FDA."

Alterity's lead candidate, ATH434, is an

oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically

to reduce -synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain in preclinical models.

As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as

Multiple System Atrophy (MSA). Phase 1 studies have demonstrated the agent is well tolerated and achieved brain levels comparable to efficacious

levels in animal models of MSA. Positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients

with MSA demonstrated robust clinical efficacy, target engagement on key biomarkers, and a favorable safety profile. A second Phase 2

open-label biomarker trial in patients with more advanced MSA is ongoing. ATH434 has been granted Fast Track Designation by the U.S. FDA,

and Orphan Drug Designation by the U.S. FDA and the European Commission for the treatment of MSA.

About ATH434-201 Phase 2 Clinical Trial

The ATH434-201 Phase 2 clinical trial is a randomized,

double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated the efficacy,

safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable sensors were employed

to evaluate motor activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to receive ATH434 50 mg or

75 mg twice daily or matching placebo. The data showed that, compared to placebo, ATH434 produced clinically and statistically significant

improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, a functional rating scale that assesses

disability on activities of daily living affected in MSA. Additional efficacy assessments demonstrated improvement consistent with the

positive UMSARS Part I findings including trends in improved motor performance on the Parkinson's Plus rating scale, the Clinical

Global Impression of Severity Scale, and the Orthostatic Hypotension Symptom Assessment (a patient reported outcome). Wearable sensor

data indicated that ATH434 also led to increased activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect

and target engagement relative to placebo. Both dose levels stabilized or reduced iron accumulation in MSA affected brain regions with

trends in preservation of brain volume. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious

adverse events attributed to ATH434. Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091.

Biomarkers of progression in Multiple System Atrophy

(bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved

therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction

of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing

disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity's randomized

ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with clinically probable or clinically established MSA. BioMUSE

continues to provide vital information on early stage MSA patients, informs the selection of biomarkers suitable to evaluate target engagement

and preliminary efficacy, and delivers clinical data to characterize disease progression in a patient population that mirrors those currently

enrolling in the Phase 2 clinical trial.

About Multiple System Atrophy

Multiple System Atrophy (MSA) is a rare, neurodegenerative

disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of

function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound

disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability

that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that

predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein -synuclein within glia, the support cells

of the central nervous system, and neuron loss in multiple brain regions. MSA affects at least 15,000 individuals in the U.S., and while

some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology

company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused

on developing disease modifying therapies in Parkinson's disease and related disorders. Alterity recently reported positive data

for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive

Parkinsonian disorder. ATH434 is also being evaluated in a Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug

discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is

based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's website at

www.alteritytherapeutics.com.

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO

of Alterity Therapeutics Limited.

Investor and Media Contacts:

Head of Investor Relations and Business Development

Forward Looking Statements

This press release contains "forward-looking

statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.

The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes,"

"anticipates," "believes," "could," "may," "evidences" and "estimates," and

other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause

actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk

Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on

Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not

limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited

to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not

limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval,

production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company to

procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug

compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent

protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's patent

rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made

by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.

We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,

whether as a result of new information, future developments or otherwise.